![Byong Kim](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Byong Kim
Directeur/Bestuurslid bij LIPELLA PHARMACEUTICALS INC.
Vermogen: 33 440 $ op 31-05-2024
Actieve functies van Byong Kim
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
LIPELLA PHARMACEUTICALS INC. | Directeur/Bestuurslid | 01-03-2022 | - |
Independent Dir/Board Member | 01-03-2022 | - | |
CytoReason Ltd.
![]() CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | Directeur/Bestuurslid | - | - |
Independent Dir/Board Member | - | - |
Loopbaan van Byong Kim
Eerdere bekende functies van Byong Kim
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BRIDGE BIOTHERAPEUTICS, INC. | Directeur/Bestuurslid | 01-01-2016 | 01-12-2019 |
Corporate Officer/Principal | 01-01-2016 | 01-12-2019 | |
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Alkermes, Inc.
![]() Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - | - |
Oxford Bioscience Partners
![]() Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Private Equity Investor | 19-08-2009 | - |
Corporate Officer/Principal | 17-08-2009 | 19-08-2009 |
Opleiding van Byong Kim
The University of Texas at Austin | Doctorate Degree |
University of California, Berkeley | Undergraduate Degree |
Carnegie Mellon University | Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 8 |
Israël | 2 |
Zuid-Korea | 2 |
Operationeel
Corporate Officer/Principal | 4 |
Director/Board Member | 3 |
Independent Dir/Board Member | 2 |
Sectoraal
Consumer Services | 4 |
Health Technology | 4 |
Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
LIPELLA PHARMACEUTICALS INC. | Health Technology |
BRIDGE BIOTHERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Oxford Bioscience Partners
![]() Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Finance |
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Alkermes, Inc.
![]() Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
CytoReason Ltd.
![]() CytoReason Ltd. Information Technology ServicesTechnology Services CytoReason Ltd. is an Israeli company that aims to link mechanisms across diseases, treatments, and patient groups. The company is based in Tel Aviv-Yafo, Israel. The company provides a platform that connects decisions to the underlying science of drug programs. The company's team includes top immunologists, a chief medical officer, a chief data scientist, a VP of strategic alliances, a chief technology officer, and a head of commercial operations. The company focuses on immune-mediated diseases such as inflammatory bowel disease, atopic dermatitis, rheumatoid arthritis, and asthma, immuno-oncology diseases such as non-small cell lung cancer, renal cell carcinoma, and melanoma, and fibrosis diseases such as non-alcoholic steatohepatitis, systemic sclerosis, and idiopathic pulmonary fibrosis. CytoReason was founded in 2016 by Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny, Renaud Gaujoux, David Harel, and Shai Shen-Orr. David Harel has been the CEO since 2016. | Technology Services |